Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: purified talc; amaranth aluminium lake; titanium dioxide; stearic acid; magnesium stearate; macrogol 6000; indigo carmine aluminium lake; polyvinyl acetate phthalate; calcium silicate; diethyl phthalate; povidone; hypromellose; citric acid monohydrate; hyprolose - epilepsy: primary generaliszed epilepsies (petit mal absences, various forms of myoclonic epilepsies and tonic-clonic grand mal seizures). partial (focal) epilepsies either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: purified talc; magnesium stearate; titanium dioxide; stearic acid; indigo carmine aluminium lake; calcium silicate; polyvinyl acetate phthalate; hypromellose; citric acid monohydrate; diethyl phthalate; hyprolose; amaranth aluminium lake; povidone; macrogol 6000 - epilepsy: primary generalised epilepsies (petit mal absences, various forms of myoclonic epilepsies and tonic-clonic grand mal seizures). partial (focal) epilepsies either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fentanyl citrate, quantity: 785 microgram (equivalent: fentanyl, qty 500 microgram) - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - dbl fentanyl injection is indicated for analgesic action of short duration during premedication, induction and maintenance of anaesthesia and in the immediate post-operative periods. it may be used as an opioid analgesic supplement in general and regional anaesthesia.,fentanyl may be used in combination with neuroleptic agents such as droperidol as an anaesthetic premedication, for the induction of anaesthesia and as an adjunct in the maintenance of general and regional anaesthesia. the state of neurolept analgesia may be converted to neurolept anaesthesia by the concurrent administration of 65% nitrous oxide in oxygen.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - tranylcypromine sulfate, quantity: 13.68 mg (equivalent: tranylcypromine, qty 10 mg) - tablet, film coated - excipient ingredients: sucrose; erythrosine; magnesium stearate; gelatin; calcium sulfate dihydrate; maize starch; carnauba wax; titanium dioxide; hypromellose; propylene glycol; iron oxide yellow; iron oxide red; iron oxide black; cochineal - indications as at 5 october 1998: treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - betamethasone valerate, quantity: 0.24 mg/g (equivalent: betamethasone, qty 0.2 mg/g) - cream - excipient ingredients: cetomacrogol 1000; cetostearyl alcohol; white soft paraffin; liquid paraffin; purified water; chlorocresol; monobasic sodium phosphate; phosphoric acid; sodium hydroxide - indications as at 23 april 2004 : eczema includiing: atopic, infantile, stasis and discoid eczemas. besnier's (flexural) prurigo. otitis externa. neurodermatoses including lichen simplex, lichen planus. seborrheic dermatitis, contact sensitivity reactions and allergies.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - amisulpride - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

drugsrus ltd - glycopyrronium bromide - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

drugsrus ltd - glycopyrronium bromide - oral tablet - 1mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - agalsidase beta, quantity: 5.5 mg - injection, powder for - excipient ingredients: nitrogen; monobasic sodium phosphate monohydrate; mannitol; dibasic sodium phosphate heptahydrate - fabrazyme is indicated for the long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alpha-galactosidase deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - agalsidase beta, quantity: 35 mg - injection, powder for - excipient ingredients: monobasic sodium phosphate; nitrogen; dibasic sodium phosphate heptahydrate; mannitol - fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alpha-galactosidase deficiency).